Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo. A validated questionnaire assessed dyspeptic symptoms at baseline and at 3, 6, and 12 months. Endoscopies and biopsies were performed at baseline and at 3 and 12 months. There was an overall trend, although not statistically significant, for a benefit of H. pylori eradication. Of the patients in the antibiotics group, 16 of 46 (35%) had symptomatic improvement, versus 9 of 43 (21%) in the control group (P = 0.164). In a secondary analysis, it was found that of the patients without endoscopic gastric erosions, 15 of 34 (44%) in the antibiotics group and 5 of 33 (15%) of controls had symptomatic improvement (P = 0.015). Helicobacter pylori eradication did not prove to be clinically beneficial, although a tendency to symptomatic benefit was detected. Further studies are necessary to confirm the implications of endoscopic gastric erosions in these patients.

SUMMARYBackground: The protective role of Helicobacter pylori in gastro-oesophageal reflux disease has been widely discussed. Aim: To assess the risk of reflux oesophagitis in patients with functional dyspepsia after treatment for H. pylori infection. Methods: A randomized, placebo-controlled, investigator-blinded trial was carried out on 157 functional dyspeptic patients. Patients were randomized to receive lansoprazole, amoxicillin and clarithromycin (antibiotic group) or lansoprazole and identical antibiotic placebos (control group). Upper gastrointestinal endoscopy was performed at baseline, 3 and 12 months after randomization. The primary aim was to detect the presence of reflux oesophagitis. Analyses were performed on an intention-to-treat basis. Results: A total of 147 patients (94%) and 133 (85%) completed 3 months and 12 months follow-up, respectively. The eradication rate of H. pylori was 90% in the antibiotic group (74 of 82) and 1% (one of 75) in the control group. At 3 months, reflux oesophagitis was diagnosed in 3.7% (three of 82) in the antibiotic group and 4% (three of 75) in the control group (P > 0.2). At 12 months, diagnosis was established in five new cases within the first group and in four within the second (P > 0.2). No difference was found in heartburn symptoms. Conclusions: H. pylori eradication does not cause reflux oesophagitis in this western population of functional dyspeptic patients.

References1 Moy RL, Luftman DB, Nguyen QH, Amenta JS. Estrogen receptors and the response to sex hormones in angiolymphoid hyperplasia with eosinophilia. Arch Dermatol 1992; 128: 825-828. 2 Wells G, Whimster I. Subcutaneous angiolymphoid hyperplasia with eosinophilia. Br J Dermatol 1969; 81: 1-15. 3 Sebõk B, Bátai I, Anga B, Schneider I. Angiolymphoid hyperplasia with eosinophilia. Orv Hetil 1998; 139: 697-700. 4 Kimura T, Yoshimura S, Ishikawa E. Abnormal granuloma with proliferation of lymphoid tissue. Trans Soc Pathol Jpn 1948; 37: 179-180. 5 Chun SI, Ji HG. Kimura's disease and angiolymphoid hyperplasia with eosinophilia. Clinical and histopathologic differences. J Am Acad Dermatol 1992; 27: 954 -958. 6 Olsen TG, Helwig EB. Angiolymphoid hyperplasia with eosinophilia. J Am Acad Dermatol 1985; 12: 781-796. 7 Aoki M, Kimura Y. Angiolymphoid hyperplasia with eosinophilia associated with anomaluos dilatation of occipital artery: IL-5 and VEGF expression of lesional mast cells. Arch Dermatol 2002; 138: 982-984. 8 Cooper SM, Dawber RPR, Millard P. Angiolymphoid hyperplasia with eosinophilia treated by cryosurgery. JEADV 2001; 15: 486 -496. 9 Sandstad E, Asknes H, Sund S, Reinholt FP. Recurrent angiolymphoid hyperplasia with eosinophilia mimicking temporal arteritis associated with nephrotic syndrome.